These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
580 related articles for article (PubMed ID: 19079339)
1. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339 [TBL] [Abstract][Full Text] [Related]
2. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. Kominsky SL; Doucet M; Brady K; Weber KL J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147 [TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone. Masi L; Malentacchi C; Campanacci D; Franchi A Virchows Arch; 2002 May; 440(5):491-7. PubMed ID: 12021923 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894 [TBL] [Abstract][Full Text] [Related]
5. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662 [TBL] [Abstract][Full Text] [Related]
6. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Moore LD; Isayeva T; Siegal GP; Ponnazhagan S Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771 [TBL] [Abstract][Full Text] [Related]
7. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871 [TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715 [TBL] [Abstract][Full Text] [Related]
9. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181 [TBL] [Abstract][Full Text] [Related]
10. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421 [TBL] [Abstract][Full Text] [Related]
11. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Zhang F; Lee J; Lu S; Pettaway CA; Dong Z Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637 [TBL] [Abstract][Full Text] [Related]
12. Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells. Chang J; Lee C; Hahm KB; Yi Y; Choi SG; Kim SJ Oncogene; 2000 Jan; 19(1):151-4. PubMed ID: 10644990 [TBL] [Abstract][Full Text] [Related]
13. Rapid closure of midgestational excisional wounds in a fetal mouse model is associated with altered transforming growth factor-beta isoform and receptor expression. Goldberg SR; McKinstry RP; Sykes V; Lanning DA J Pediatr Surg; 2007 Jun; 42(6):966-71; discussion 971-3. PubMed ID: 17560204 [TBL] [Abstract][Full Text] [Related]
14. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Deckers M; van Dinther M; Buijs J; Que I; Löwik C; van der Pluijm G; ten Dijke P Cancer Res; 2006 Feb; 66(4):2202-9. PubMed ID: 16489022 [TBL] [Abstract][Full Text] [Related]
15. Expression of mRNA coding for TGF-beta and its receptors in irradiated human breast carcinoma MCF-7 cells differing in their sensitivity to doxorubicin. Chorna I; Fedorenko O; Datsyuk L; Stoika R Exp Oncol; 2005 Jun; 27(2):156-8. PubMed ID: 15995636 [TBL] [Abstract][Full Text] [Related]
16. Expression of TGF-beta and its receptors in murine fetal and adult dermal wounds. Cowin AJ; Holmes TM; Brosnan P; Ferguson MW Eur J Dermatol; 2001; 11(5):424-31. PubMed ID: 11525949 [TBL] [Abstract][Full Text] [Related]
17. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924 [TBL] [Abstract][Full Text] [Related]
18. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006 [TBL] [Abstract][Full Text] [Related]
19. TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Imamichi Y; Waidmann O; Hein R; Eleftheriou P; Giehl K; Menke A Biol Chem; 2005 Mar; 386(3):225-36. PubMed ID: 15843168 [TBL] [Abstract][Full Text] [Related]